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Abstract
BACKGROUND—Blood pressure (BP) and cholesterol are major modifiable risk factors for 
cardiovascular disease (CVD), but effects of exposures during young adulthood on later life CVD 
risk have not been well quantified.
OBJECTIVE—The authors sought to evaluate the independent associations between young adult 
exposures to risk factors and later life CVD risk, accounting for later life exposures.
METHODS—The authors pooled data from 6 U.S. cohorts with observations spanning the life 
course from young adulthood to later life, and imputed risk factor trajectories for low-density 
lipoprotein (LDL) and high-density lipoprotein cholesterols, systolic and diastolic BP starting 
from age 18 years for every participant. Time-weighted average exposures to each risk factor 
during young (age 18 to 39 years) and later adulthood (age ≥40 years) were calculated and linked 
to subsequent risks of coronary heart disease (CHD), heart failure (HF), or stroke.
RESULTS—A total of 36,030 participants were included. During a median follow-up of 17 years, 
there were 4,570 CHD, 5,119 HF, and 2,862 stroke events. When young and later adult risk factors 
were considered jointly in the model, young adult LDL ≥100 mg/dl (compared with <100 mg/dl) 
was associated with a 64% increased risk for CHD, independent of later adult exposures. 
Similarly, young adult SBP ≥130 mm Hg (compared with <120 mm Hg) was associated with a 
37% increased risk for HF, and young adult DBP ≥80 mm Hg (compared with <80 mm Hg) was 
associated with a 21% increased risk.
CONCLUSIONS—Cumulative young adult exposures to elevated systolic BP, diastolic BP and 
LDL were associated with increased CVD risks in later life, independent of later adult exposures.
Keywords
blood pressure; cholesterol; coronary heart disease; heart failure; stroke; young adulthood
Blood pressure (BP) and cholesterol are major modifiable cardiovascular disease (CVD) risk 
factors and key components of risk prediction algorithms (1–4). Compared with BP or 
cholesterol measured at the time of risk assessment (usually in middle or older age), average 
levels over many years may more accurately capture an individual’s long-term risk factor 
exposure history and may offer additional prognostic information (5–10). Young adult 
exposures to elevated BP and cholesterol are associated with subclinical atherosclerosis in 
middle age as well as risk for CVD events that occur decades later (8–15). However, it is 
unclear whether exposures to risk factors during young adulthood contribute independently 
to future CVD risk above and beyond later life exposures (14). Because most cohort studies 
are restricted in their baseline age range, and few cohorts followed participants from young 
adulthood to later life, it has been challenging to elucidate independent contributions of risk 
factor exposures during early versus later adulthood because few cohorts measured both 
young adult exposures and substantial numbers of CVD events, which primarily occur much 
later in life.
Zhang et al. Page 2
J Am Coll Cardiol. Author manuscript; available in PMC 2019 September 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
By pooling and harmonizing data from 6 prospective cohort studies with repeated risk factor 
measurements, our study sought to model complete risk factor trajectories starting at 18 
years of age until the end of follow-up for all study participants, and used those trajectories 
to estimate the independent associations of risk factor exposures during young adulthood (18 
to 39 years of age) and later adulthood (≥40 years of age) with subsequent risks of coronary 
heart disease (CHD), heart failure (HF), and stroke.
METHODS
STUDY DESIGN AND COHORTS.
The present analysis was based on data from 6 large, community-based, prospective cohort 
studies: 1) the ARIC (Atherosclerosis Risk In Communities) study (16); 2) the CARDIA 
(Cardiovascular Risk Development in Young Adults) study (17); 3) the CHS study 
(Cardiovascular Health Study) (18); 4) the FHS-O cohort (Framingham Heart Study 
Offspring Cohort) (19); 5) the Health ABC (Health, Aging and Body Composition) study 
(20); and 6) the MESA study (Multi-Ethnic Study of Atherosclerosis) (21). Details of the 
design of each study are reported in the Online Methods in the Online Appendix. All data 
were centralized at Columbia University for pooling, harmonization, and analysis, as part of 
the NHLBI (National Heart, Lung, and Blood Institute) Pooled Cohorts study (22). The 
present analysis was restricted to participants ≥18 years of age without known CVD at 
baseline and with at least 1 nonmissing value for each CVD risk factor (Online Figure 1). 
The final sample size comprised 36,030 individuals.
CLINICAL DATA COLLECTION AND FOLLOW-UP FOR CVD EVENTS.
Details of clinical data collection and events follow-up are reported in the Online Methods. 
The primary CVD risk factors of interest in the current analysis were systolic blood pressure 
(SBP), diastolic blood pressure (DBP), low-density lipoprotein (LDL) cholesterol, and high-
density lipoprotein (HDL) cholesterol. The primary outcomes of interest for our analysis 
were incident CHD (defined as myocardial infarction or CHD death), HF, and stroke 
(ischemic or hemorrhagic). Events were ascertained and adjudicated using each cohort’s 
specific protocol, and the details are provided in Online Table 1.
IMPUTATION OF CVD RISK FACTORS ACROSS THE LIFE COURSE.
Most studies are restricted in age range and therefore did not directly measure CVD risk 
factors during both early and later life (for example, participants in the ARIC study were 
enrolled after 45 years of age, and therefore, their CVD risk factor levels before age 45 years 
were not observed). We previously developed a method to impute risk factors across the life 
course (14,23). Details of the method have been described elsewhere (23). Briefly, we 
pooled data from multiple cohorts (which together span the adult life course), and leveraged 
the risk factor patterns observed in the younger cohorts to impute unobserved young adult 
exposures in the older cohorts, and vice versa. We used linear mixed models to estimate 
latent trajectories underlying the observed values for each participant, and imputed risk 
factor levels annually from age 18 years through the end of follow-up for each participant. 
Examples of imputed LDL trajectories for 18 randomly selected participants (3 participants 
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per study) are illustrated in Online Figure 2. Results of the validation of the imputation 
method are shown in Online Figure 3.
STATISTICAL ANALYSES.
Using the imputed trajectories, we calculated period-specific time-weighted averages 
(TWAs) of SBP, DBP, LDL, and HDL levels as summary measures of young (18 to 39 years 
of age) and later adult (≥40 years of age) exposures to CVD risk factors (Online Figure 2).
We used Cox proportional hazards models for each CVD outcome to calculate hazard ratios 
(HRs) for young adult and later life risk factor exposures. We used age as the time scale, 
with the origin for time to event set at the first in-person visit or age 40 years, whichever 
occurred later. Each Cox model was stratified by study cohort and adjusted for race/
ethnicity, sex, birth year, body mass index, smoking status, cigarettes smoked per day, 
diabetes, years with diabetes, use of lipid-lowering and antihypertensive medications, and 
the early and later adult TWAs of other primary CVD risk factors of interest. For example, 
the model for LDL cholesterol was simultaneously adjusted for early and later adult 
exposures to SBP, DBP, and HDL, as well as for other time-varying covariates mentioned 
earlier in the text. The proportional hazards assumption was checked by plotting the 
log(−log(survival)) versus log(survival time) and by using Schoenfeld residuals. Tests for 
linear trend in association with the outcome across the categories of each risk factor were 
conducted by including a variable with the median level of each category in the models.
To account for estimation error in imputed risk factors trajectories and TWAs, we used 
multiple imputation techniques based on parametric bootstrap to obtain 30 imputed datasets. 
Survival analyses of the associations between risk factors and CVD outcomes were 
performed on each imputed dataset, and a summary HR and corresponding 95% confidence 
interval (CI) were calculated across all 30 imputations using established methods (the 
summary HR and 95% CI can be interpreted the same way as those generated from a 
standard Cox model) (24).
To examine the robustness and consistency of our findings, we performed several sensitivity 
analyses. These included examining the associations between non-HDL cholesterol and 
CVD outcomes instead of LDL; further adjusting for the most recent directly observed value 
carried forward; stratifying by sex and race (whites and blacks); excluding individuals who 
ever used antihypertensive or lipid-lowering medications; repeating analyses by cohort, and 
leaving out 1 cohort at a time to confirm that our findings were not driven by any single 
study. All analyses were performed using STATA version 14 (StataCorp LP, College Station, 
Texas).
RESULTS
The average observed age of study participants at their first in-person examination was 52.7 
years, ranging from 24.9 years in the CARDIA study to 73.5 years in the Health ABC study 
(Table 1). Men composed 44.5% of all participants, and 68.5% self-identified as white. The 
majority of participants (95%) contributed >1 direct measurement over time (mean 5.1 per 
person) (Table 2). Time-weighted average measurements of SBP, DBP, LDL, and HDL from 
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young adulthood were strongly correlated with their later life averages (Online Table 2). 
Although relatively few participants had BP ≥130/80 mm Hg or LDL ≥160 mg/dl during 
young adulthood, many of them were exposed to nonoptimal levels of risk factors, 
particularly LDL ≥100 but <160 mg/dl (Online Table 3).
During a median follow-up of 17 years, there were a total of 4,570 incident CHD, 5,119 HF, 
and 2,862 stroke events (Table 2). When young adult and later life risk factor exposures were 
considered jointly in the same model, exposures to elevated DBP and LDL during young 
adulthood were associated with an increased risk of CHD, independent of later life 
exposures (Central Illustration, Figure 1). Specifically, compared with DBP <70 mm Hg, 
multivariable-adjusted HRs for CHD were 1.08 (95% CI: 0.94 to 1.24) for DBP 70 to 79 mm 
Hg, 1.21 (95% CI: 1.02 to 1.43) for DBP 80 to 89 mm Hg, and 1.21 (95% CI: 0.62 to 2.38) 
for DBP ≥90 mm Hg (p value for trend = 0.04). Compared with LDL <100 mg/dl, adjusted 
HRs were 1.62 (95% CI: 1.25 to 2.10) for LDL 100 to 129 mg/dl, 1.89 (95% CI: 1.43 to 
2.50) for LDL 130 to 159 mg/dl, and 2.03 (95% CI: 1.47 to 2.82) for LDL ≥160 mg/dl (p 
value for trend <0.001). When the top 3 LDL categories were combined, young adult 
exposure to LDL ≥100 mg/dl was associated with an adjusted HR of 1.64 (95% CI: 1.27 to 
2.11) for CHD, compared with LDL <100 mg/dl.
Nonoptimal SBP and DBP in young adulthood were independently associated with 
subsequent risk of HF (Figure 2). Compared with SBP <120 mm Hg, young adult SBP ≥130 
mm Hg was associated with an adjusted HR of 1.37 (95% CI: 1.17 to 1.61) for HF. 
Compared with DBP <80 mm Hg, young adult DBP ≥80 mm Hg was associated with an HR 
of 1.21 (95% CI: 1.04 to 1.41) for HF.
For stroke events, none of the young adult exposures were independently associated with 
incident stroke, whereas later adult exposures to high SBP or DBP were strong predictors of 
stroke risk (Figure 3).
We found similar patterns of association in sensitivity analyses. The associations between 
non-HDL cholesterol and incident CVD events were largely consistent with what we saw 
with LDL (Online Figure 4), When further adjusting for the most recent directly observed 
exposures in the models, the associations between young adult exposure and CVD outcomes 
remained unchanged, whereas the strength of associations between later adult exposures and 
CVD outcomes were slightly attenuated (Online Figures 5 to 7). The patterns of the 
associations were similar among men and women (Online Figures 8 to 10), and among 
whites and blacks (Online Figures 11 to 13; all p-interactions by sex or by race were >0.10). 
Among the 9,955 participants who never used antihypertensive or lipid-lowering 
medications, young adult DBP and LDL remained significantly associated with CHD and 
HF events with even stronger associations compared with the main analysis (Online Figures 
14 to 16). The analyses leaving out 1 study at a time (Online Figures 17 to 20) or by each 
study (Online Figures 21 to 24) also found consistent results.
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DISCUSSION
In this analysis of pooled data from 6 large prospective U.S. cohort studies, we found that 
young adult exposures to elevated DBP and LDL were associated with incident CHD, and 
young adult exposure to elevated SBP and DBP were associated with incident HF, 
independent of later adult exposures (Central Illustration). These findings suggest that 
exposures to elevated SBP, DBP, and LDL during young adulthood contribute independently 
to later life CHD and HF risks.
Elevated BP is a well-established CVD risk factor and consistently proved to be a key young 
adult and later adult CVD risk factor in our analyses (1–4). Past studies have shown that 
early life exposure to high BP are associated with signs of subclinical atherosclerosis at 
middle age (8,9). In the CARDIA study, both cumulative BP exposure and long-term BP 
trajectories during young adulthood were associated with coronary atherosclerosis 2 decades 
later, independent of mid-life BP levels (8,9). Similarly, in 18,881 men from the Harvard 
Alumni Health Study, high BP in young adulthood was associated with allcause, CVD, and 
CHD mortality, after adjusting for middle-age hypertension (11). Although these studies 
controlled for current BP in their analyses, they did not tease apart the relative importance of 
early versus later life exposures in predicting future CVD risk (14). Our analysis modeled 
average young adult and later adult BP exposures jointly, and found that both early and later 
adult BP were associated with subsequent risks of CHD and HF, with DBP being the 
dominant predictor in early adulthood and SBP in later adulthood. This is consistent with 
findings from the Framingham Heart Study, which showed that DBP was a stronger 
predictor of CHD risk than SBP in participants <50 years of age, and there was a gradual 
shift from DBP to SBP as predictors of CHD with increasing age (25). It may be that 
diminished peripheral amplification of SBP due to pulse wave reflection in young adults 
confounds detection of those with moderately raised central SBP in this age group (25). As a 
consequence, peripheral DBP may be superior to SBP in predicting CVD risks in young 
adults (25). With age- and atherosclerosis-dependent increases in large artery stiffness, the 
difference between central and peripheral SBP narrows, thereby improving the predictive 
utility of peripheral SBP while diminishing that of DBP (25). The J-shaped association 
between later adult DBP and CHD risk observed in our analysis is consistent with previous 
studies and may represent an epiphenomenon of increased arterial stiffness in older adults 
leading to a higher peripheral SBP, a lower DBP, and a wider pulse pressure (25–27).
Elevated levels of LDL cholesterol in young adulthood were strongly and independently 
associated with later life CHD in our analysis. Early reports from large prospective cohort 
studies demonstrated that LDL measured once during young adulthood was associated with 
CHD events decades later; however, these analyses did not account for later life LDL 
(12,15). The CARDIA study reported that nonoptimal levels of LDL cholesterol during 
young adulthood were associated with signs of subclinical coronary atherosclerosis in 
middle age independent of mid-life LDL levels (10). The Framingham Offspring Study 
showed that cumulative exposure to hyperlipidemia during ages 35 to 55 years was 
associated with an increased risk of later life CHD in a dose-dependent fashion, after 
controlling for non-HDL cholesterol at 55 years of age (13). Our study extends these 
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previous reports by further delineating and quantifying the independent contributions of 
average young adult versus later adult LDL exposure to future CHD, HF, and stroke risk.
The stronger association between young adult LDL and subsequent CHD risk, and weaker 
association for later adult LDL is likely explained by the relatively high heritability of LDL, 
particularly during young adulthood (heritability >70%) (28,29), compared with other CVD 
risk factors such as BP and HDL (30). Thus, exposure to high LDL levels during young 
adulthood is more likely driven by genetic determinants, and genetically determined LDL 
level is an important cause of atherosclerosis early in life; whereas later in life, 
atherosclerosis is likely driven by the same behavioral and environmental factors that affect 
the other risk factors included in our models (i.e., BP, diabetes, and smoking) (30–32). 
Mendelian randomization studies demonstrated that early life LDL is a strong causal 
determinant of CHD risk that cannot be captured by later life LDL alone (33–35). Prolonged 
low LDL levels beginning early in life due to genetic variation is associated with a 
substantially greater reduction in CHD risk compared with pharmacological LDL-lowering 
later in life (33–35). Because participants were more likely to be started on lipid-lowering 
medication as they grew older, the higher prevalence of lipid medication use during later 
adulthood may have also contributed to the weaker association between later life LDL and 
CHD. However, when restricting our analysis to participants who never used lipid-lowering 
medications, we observed a similar pattern of associations and in fact an even stronger 
association between early adult LDL and CHD.
Our results add to accumulating evidence that young adulthood is a critical period when 
exposure to suboptimal BP or cholesterol is particularly harmful, and maintaining optimal 
levels of BP and LDL throughout young adulthood could yield substantial lifetime CVD 
prevention benefits (14). However, young adults are difficult to reach by way of traditional, 
clinic-based preventive programs: they are transitioning between pediatric and adult-
centered models of care (36); they often lack health insurance or experience frequent gaps in 
insurance coverage (37); and their use of ambulatory medical care and adherence to 
preventive health guidelines are the lowest of any age group (36,38). Data from National 
Health and Nutrition Examination Surveys showed that young adults lagged behind in 
awareness, treatment, and control of high BP and LDL compared with middle-aged and 
older adults (39,40), and were especially unlikely to be aware of borderline levels of BP and 
cholesterol, which were associated with future risk of CHD and HF in our study (41). Even 
when informed about a cholesterol screening result that indicates they are at high risk for 
future CVD, young adults may discount the importance of such results for their current 
health, believing they have time to change their health behaviors and mitigate their risk (42). 
Implementing preventive programs targeting individual young adults will require novel 
prevention program models that are community- and/or web-based, patient-centered, mobile, 
and account for cognitive bias in future CVD risk perception. Population-wide policies to 
promote healthful foods, modify the built environment to promote physical activity, and 
lower structural barriers to accessing healthy lifestyle choices can augment individual-level 
screening and treatment.
Current U.S. guidelines for treatment of high cholesterol and high BP advise using 
atherosclerotic CVD (ASCVD) risk to guide treatment decisions (43,44). The 2017 
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American College of Cardiology/American Heart Association guideline for high BP 
recommends pharmacological treatment for stage one hypertension (SBP 130 to 139 mm Hg 
or DBP 80 to 89 mm Hg) for younger adults without chronic kidney disease or diabetes only 
if 10-year ASCVD risk is ≥10% (43). The 2018 American College of Cardiology/American 
Heart Association cholesterol guideline emphasizes the importance of assessment of 30-year 
or lifetime ASCVD risk in young adults, but statin treatment of high cholesterol is 
recommended for young adults with LDL <190 mg/dl only if with long-standing diabetes or 
a concomitant higher-risk condition (44). The majority of the young adults with nonoptimal 
risk factors have low 10-year ASCVD risk and are not likely to receive either 
pharmacological interventions or advice to pursue lifestyle measures (i.e., weight loss, heart-
healthy diet), if they are screened at all (45–47). Pharmacological BP and LDL lowering 
may benefit selected young adults at high risk for premature ASCVD (36,47,48). The 
currently ongoing ECAD (Eliminate Coronary Artery Disease) trial is designed to address 
the question of whether incident ASCVD events can be more effectively prevented by early 
initiation of statin-based LDL lowering in young and middle-aged adults who are not yet 
candidates for guideline-based pharmacological LDL lowering due to low 10-year ASCVD 
risk (47).
STUDY STRENGTHS AND LIMITATIONS.
Our study has several strengths. By pooling and harmonizing data from multiple prospective 
cohort studies with repeated observations that span the adult life course, we were able to 
model long-term risk factor trajectories from age 18 years for each individual, and tease 
apart the independent contributions of exposures during early versus later life to future CVD 
risk. High-quality risk factor and outcome assessments, large sample size, and long follow-
up duration also allowed us to more reliably estimate the associations between CVD risk 
factors with less common outcomes such as stroke, controlling for confounding from a 
comprehensive set of variables.
A few limitations of this study need to be considered. Our study relied on imputed risk 
factor levels before 40 years of age, because the majority of the cardiovascular cohort 
studies are restricted in age range and did not measure risk factors during both early and 
later life. Future studies are needed to validate our findings in cohorts with longer follow-up 
spanning from young adulthood to later life. The risk factor trajectories and TWAs are 
subject to imputation error; however, imputation error in our study is likely nondifferential, 
and trajectory estimates for individuals with relatively fewer observed measurements are 
subject to extra “shrinkage” toward the sample means (14). Therefore, our estimates of the 
association between risk factors and CVD outcomes are likely conservative and biased 
towards the null. Our study reported nominal p values without adjustment for multiple 
testing. However, we performed various sensitivity analyses and found largely consistent 
results across the board, supporting the robustness of the main findings.
CONCLUSIONS
This pooled U.S. cohorts study of over 36,000 participants found that young adult exposures 
to raised DBP and LDL levels were associated with later life CHD risk, and young adult 
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SBP and DBP were associated with later life HF risk, independent of later adult exposures. 
These findings suggest that investment now in programs to control modifiable risk factors 
during young adulthood has the potential to reduce the future burden of CVD.
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ABBREVIATIONS AND ACRONYMS
ASCVD atherosclerotic cardiovascular disease
BP blood pressure
CHD coronary heart disease
CI confidence interval
CVD cardiovascular disease
DBP diastolic blood pressure
HDL high-density lipoprotein
HF heart failure
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HR hazard ratio
LDL low-density lipoprotein
SBP systolic blood pressure
TWA time-weighted average
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Young adults with elevated Levels of blood pressure and Low-density Lipoprotein 
cholesterol are at greater risk of cardiovascular disease Later in adulthood, independent 
of subsequent exposure to these risk factors.
TRANSLATIONAL OUTLOOK:
Cardiovascular disease prevention programs should be coupled with policies that promote 
risk awareness and reduce barriers to accessing healthy Lifestyle choices among young 
adults.
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FIGURE 1. Associations Between Young Adult and Later Adult Risk Factor Exposures and 
Incident CHD
TWA exposures to SBP, DBP, LDL, and HDL from young adulthood (18 to 39 years of age) 
and later adulthood (≥40 years of age) were included simultaneously in the same model. 
Models were stratified by study cohort and adjusted for race/ethnicity, sex, birth year, BMI, 
smoking status, cigarettes smoked per day, diabetes, years with diabetes, use of lipid-
lowering and antihypertensive medications, and the early and later adult TWAs of other risk 
factors. Exposures to elevated DBP and LDL during young adulthood were associated with 
an increased risk of CHD, independent of later life exposures. BMI = body mass index; 
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CHD = coronary heart disease; CI = confidence interval; DBP = diastolic blood pressure; 
HDL = high-density lipoprotein; HR = hazard ratio; LDL = low-density lipoprotein; SBP = 
systolic blood pressure; TWA = time-weighted average.
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FIGURE 2. Associations Between Young Adult and Later Adult Risk Factor Exposures and 
Incident HF
TWA exposures to SBP, DBP, LDL, and HDL from young adulthood (18 to 39 years of age) 
and later adulthood (≥40 years of age) were included simultaneously in the same model. 
Model adjustments were the same as in Figure 1. Exposures to elevated SBP and DBP 
during young adulthood were associated with an increased risk of heart failure, independent 
of later life exposures. HF = heart failure; other abbreviations as in Figure 1.
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FIGURE 3. Associations Between Young Adult and Later Adult Risk Factor Exposures and 
Incident Stroke
TWA exposures to SBP, DBP, LDL, and HDL from young adulthood (18 to 39 years of age) 
and later adulthood (≥40 years of age) were included simultaneously in the same model. 
Model adjustments were the same as in Figure 1. None of the young adult risk factors were 
independently associated with incident stroke, whereas later adult exposures to high SBP 
and DBP were strongly associated with stroke risk. Abbreviations as in Figure 1.
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CENTRAL ILLUSTRATION. Associations of Blood Pressure and Cholesterol Levels During 
Young Adulthood With Cardiovascular Events Later in Life
Study of 36,030 U.S. adults found that exposures to elevated SBP, DBP, and LDL during 
young adulthood (18 to 39 years of age) were associated with increased CHD and heart 
failure risks in later life, independent of later adult exposures. BP = blood pressure; CHD = 
coronary heart disease; CI = confidence interval; DBP = diastolic blood pressure; HR = 
hazard ratio; LDL = low-density lipoprotein; SBP = systolic blood pressure; TWA = time-
weighted average.
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